îæ€çŽ¢
îæ€çŽ¢
î
Polaryx Therapeutics Ord Shs
PLYXîãŠã©ãããªã¹ãã«è¿œå
2.670USD
-0.740-21.70%
çµå€Â 05/15, 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
126.41Mæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
î
詳现æ å ± Polaryx Therapeutics Ord Shs äŒæ¥å
Polaryx Therapeutics Ord Shsã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãPLYX
äŒç€ŸåPolaryx Therapeutics Inc
äžå Žæ¥Feb 02, 2026
æé«çµå¶è²¬ä»»è
ãCEOãYang (Alex Keun Mo)
åŸæ¥å¡æ°- -
蚌åžçš®é¡Ordinary Share
決ç®ææ«- -
æ¬ç€Ÿæåšå°- -
éœåž- -
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœ- -
éµäŸ¿çªå·- -
é»è©±çªå·- -
ãŠã§ããµã€ã- -
äŒæ¥ã³ãŒãPLYX
äžå Žæ¥Feb 02, 2026
æé«çµå¶è²¬ä»»è
ãCEOãYang (Alex Keun Mo)
Polaryx Therapeutics Ord Shsã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
,
,
--
--
Mr. Alex Yang, J.D.
Mr. Alex Yang, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Lisa L. Bollinger, M.D.
Dr. Lisa L. Bollinger, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. G. Michael Landis, CPA
Mr. G. Michael Landis, CPA
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Mr. Andrew O
Mr. Andrew O
Chief Investment Officer
Chief Investment Officer
--
--
Dr. Mitchel Berger, M.D.
Dr. Mitchel Berger, M.D.
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Francis A. Braun
Mr. Francis A. Braun
Independent Director Nominee
Independent Director Nominee
--
--
Dr. Charles S. Ryan, J.D., Ph.D.
Dr. Charles S. Ryan, J.D., Ph.D.
Independent Director Nominee
Independent Director Nominee
--
--
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
,
,
--
--
Mr. Alex Yang, J.D.
Mr. Alex Yang, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Lisa L. Bollinger, M.D.
Dr. Lisa L. Bollinger, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. G. Michael Landis, CPA
Mr. G. Michael Landis, CPA
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Mr. Andrew O
Mr. Andrew O
Chief Investment Officer
Chief Investment Officer
--
--
Dr. Mitchel Berger, M.D.
Dr. Mitchel Berger, M.D.
Independent Director Nominee
Independent Director Nominee
--
--
åçå èš³
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äºæ¥å¥
å°åå¥
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
æ ªäž»
æŽæ°æå»: Sun, May 10
æŽæ°æå»: Sun, May 10
æ ªäž»çµ±èš
çš®é¡
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Mstone Partners Healthcare Ltd
48.04%
Koh (Gershon)
11.67%
Rush University Medical Center
8.04%
Young Poong Pharmaceutical Co, Ltd.
5.24%
The Vanguard Group, Inc.
3.52%
ä»ã®
23.49%
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Mstone Partners Healthcare Ltd
48.04%
Koh (Gershon)
11.67%
Rush University Medical Center
8.04%
Young Poong Pharmaceutical Co, Ltd.
5.24%
The Vanguard Group, Inc.
3.52%
ä»ã®
23.49%
çš®é¡
æ ªäž»çµ±èš
æ¯ç
Corporation
61.32%
Individual Investor
11.68%
Investment Advisor
7.28%
Investment Advisor/Hedge Fund
0.30%
ä»ã®
19.41%
æ©é¢æè³å®¶ä¿ææ ª
îæŽæ°æå»: Fri, May 1
æŽæ°æå»: Fri, May 1
å ±åæé
æ©é¢æè³å®¶æ°
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
2026Q1
6
3.59M
7.58%
+3.59M
æ ªäž»åå
îäŒç€Ÿå
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
å€åç
æ¥ä»
Mstone Partners Healthcare Ltd
22.74M
48.04%
+22.74M
--
Feb 02, 2026
詳现ãèŠã
é¢é£ETF
îéæå
æ¯ç
ããŒã¿ãªã
é åœé
îéå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã
æ¥ä»
é
åœé
æš©å©ç¢ºå®æ¥
æ¯ææ¥
é
åœèœã¡æ¥
ããŒã¿ãªã
æ ªåŒåå²
îæ¥ä»
é
åœèœã¡æ¥
çš®é¡
æ¯ç
ããŒã¿ãªã
æ¥ä»
é
åœèœã¡æ¥
çš®é¡
æ¯ç
ããŒã¿ãªã
